



2025 Formulary Changes

EFFECTIVE DATE: 08/01/2025

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier	Change Type	Change Reason
APTOM 600 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 400 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 800 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 30 MG-15MG ORAL TABLET SEQ	TOLVAPTAN 30 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 90 MG-30MG ORAL TABLET SEQ	TOLVAPTAN 90 MG-30MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 60 MG-30MG ORAL TABLET SEQ	TOLVAPTAN 60 MG-30MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 15 MG-15MG ORAL TABLET SEQ	TOLVAPTAN 15 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 45 MG-15MG ORAL TABLET SEQ	TOLVAPTAN 45 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 200 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

EFFECTIVE DATE: 06/01/2025

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier	Change Type	Change Reason
PURIXAN 20 MG/ML ORAL ORAL SUSP	MERCAPTOPURINE 20 MG/ML ORAL ORAL SUSP-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

EFFECTIVE DATE: 04/01/2025

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier	Change Type	Change Reason
TRUSELTIQ 75 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
TRUSELTIQ 50 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
TRUSELTIQ 100 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
MESNEX 400 MG ORAL TABLET	MESNA 400 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
TRUSELTIQ 125 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED

EFFECTIVE DATE: 02/01/2025

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier
SPRYCEL 70 MG ORAL TABLET	DASATINIB 70 MG ORAL TABLET-5
SPRYCEL 80 MG ORAL TABLET	DASATINIB 80 MG ORAL TABLET-5
SPRYCEL 140 MG ORAL TABLET	DASATINIB 140 MG ORAL TABLET-5
SPRYCEL 20 MG ORAL TABLET	DASATINIB 20 MG ORAL TABLET-5
SPRYCEL 50 MG ORAL TABLET	DASATINIB 50 MG ORAL TABLET-5
SPRYCEL 100 MG ORAL TABLET	DASATINIB 100 MG ORAL TABLET-5

CHANGE TYPE

BRAND DELETION, ADD FRF GENERIC

CHANGE REASON

REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT